B2Digital Reports 126% Q/Q Topline Growth, Projects Current Quarter Acceleration, Major Expansion in Fitness Facility Strategy

Tampa, FL – ( NewMediaWire ) – December 03, 2020 – B2Digital Incorporated (the “Company” or “B2Digital”) (OTCMKTS:BTDG), the premier development league for mixed martial arts (“MMA”), is excited to update shareholders on the Company’s outlook and the accelerating organic and strategic growth underway in its Gym segment, as well as its performance related to this strategy during the three months ended September 30, 2020, and its expectations for related performance during the current quarter ending December 31, 2020, and beyond.

Note that projections and guidance outlined below assume an absence of further regulatory lockdowns related to Covid-19 as well as the widespread distribution of a safe and effective vaccine during 2021.

“Based on the strategy we have in place – and the assumption that we don’t see major new pandemic-related shutdowns that impact the business – we are targeting $4-5 million on the topline over the rolling forward next twelve months,” commented Greg P. Bell, CEO of B2Digital. “This is based on the growth we are seeing now and the continued successful implementation of the company’s roll-up strategy in our Fitness Facility segment, which is the real breadwinner in our broad vision. We are already on pace to more than double the topline on a sequential quarterly basis into year-end.”

During the three months ended September 30, 2020, B2Digital saw a 76% jump in Gym revenues on a sequential quarterly basis. In addition, the Company increased overall revenues across segments totaling topline growth on a sequential quarterly basis during the quarter of 126%. Management also notes that, based on performance thus far and an assumption of no new pandemic-related shutdowns relevant to its current fitness facility operations, it projects a pace to achieve double the top line revenue in Q3 compared to Q2 of this year for the three months ending December 31, 2020.

In addition, the Company plans to continue its roll-up strategy in the fitness facility market over the coming twelve months. The Company’s objective is to acquire one to two new gym facilities every quarter with our goal to increase these acquisitions as the spread of Covid-19 decreases nationally. Thus far, each acquisition the Company makes in the fitness facility space is believed to represent at least $400K per year in rolling forward next twelve-month revenues based on past historical performance.

At this pace, given current metrics and assumptions, including no major return of mandated pandemic-related shutdowns relevant to its current fitness facilities, the Fitness Facility segment could achieve just shy of $4 million in revenues over the rolling forward next twelve months if the company’s acquisition objectives are executed as planned. Paired with a conservative assumption of $75K – $100K in monthly revenues from its live MMA events, encompassing 3 planned fights a month at current revenue achievement rates per fight, the Company believes it has the potential to achieve total revenues of at least $4 to $5 million over the rolling forward twelve months.

“Each acquisition we make in the Fitness Facility space is

Read more

AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma

Paris, October 20, 2020, 9.15pm

AB Science announces positive top-line Phase 3 results
 for oral masitinib in severe asthma

This is the second Phase 3 study to demonstrate efficacy for masitinib in severe asthma

AB Science SA (Euronext – FR0010557264 – AB) today announced that the Phase 3 study (AB14001) evaluating oral masitinib in severe asthma uncontrolled by high-dose inhaled corticosteroids (ICS) and with eosinophil level >150 cells/μL met its primary endpoint.

The pre-specified primary analysis was rate of severe asthma exacerbations, with masitinib demonstrating a statistically significant 29% reduction in severe exacerbations relative to placebo (p=0.022). The frequency of severe asthma exacerbations was 0.43 in the masitinib arm, versus 0.62 in the placebo arm. Duration of exposure was well-balanced between the treatment-arms (16 months in the masitinib arm and 17 months in the placebo arm). Sensitivity analysis based on the rate of moderate and severe asthma exacerbations was consistent with the primary analysis and detected a statistically significant 31% reduction in exacerbations (p=0.005) between masitinib and placebo. The frequency of moderate and severe asthma exacerbations was 0.55 in the masitinib arm, versus 0.80 in the placebo arm.

This is the second time that masitinib has demonstrated efficacy in reducing severe asthma exacerbations in patients with severe asthma. The treatment effect observed in study AB14001 is comparable with the effect previously reported for study AB07015. In that first phase 3 study, which evaluated masitinib in severe asthma uncontrolled by oral corticosteroids (OCS), masitinib significantly (p=0.010) reduced the rate of severe asthma exacerbations by 35% as compared with placebo. The frequency of severe asthma exacerbations in study AB07015 was 0.34 in the masitinib arm, versus 0.45 in the placebo arm. Duration of exposure was also well-balanced between the treatment arms (13 months in both treatment arms).
Safety was consistent with the known tolerability profile for masitinib.

Detailed results will be presented at an upcoming medical meeting.

The study AB14001 enrolled patients with blood eosinophil level >150 cells/μL, which differs from the population usually addressed by biological treatments, targeting patients with high eosinophils (>300 cells/μL or above) defined as Th2-high eosinophilic asthma.

Masitinib is a first in class drug in severe asthma, distinct from biological treatments targeting type-2 high eosinophilic phenotypes of asthma. Masitinib has a dual mechanism of action, targeting mast cells and PDGFR signaling that are both involved in airway remodeling associated with severe asthma. It has also been shown that increased mast cell activity is associated with both eosinophilic (Th2-high) and non-eosinophilic (Th2-low) asthma phenotypes. Furthermore, masitinib is orally administered, whereas biologics are sub-cutaneous, which is an advantage because oral administration is less of a burden for patients and facilitates compliance for long-term use.

There is still a need for effective therapy of patients with severe asthma. Biologics are established in first line treatment in severe asthma patients with blood eosinophil levels of ≥300 cells/µL. However, these therapies have limited efficacy in reducing severe asthma exacerbations for severe asthmatics with blood eosinophil levels of <300 cells/µL. In

Read more